Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab.
Clin Med Insights Oncol., 6:287-303 (2012)
Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.
Clin. Cancer Res., Jul;17(14):4799-805 (2011)
PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake.
Clin. Cancer Res., Apr;17(8):2400-9 (2011)
Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012.
J. Clin. Oncol., Mar;29(8):1014-21 (2011)
The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors.
J Natl Compr Canc Netw., Oct;7 Suppl 7:S1-29; quiz S30 (2009)
Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012).
Breast Cancer Res. Treat., Jan;119(2):391-8 (2010)
Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study.
Breast Cancer Res. Treat., Nov;118(1):81-7 (2009)
Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.
J. Clin. Oncol., Oct;26(30):4875-82 (2008)
Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer.
J. Clin. Oncol., Sep;26(27):4449-57 (2008)
Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP).
Breast Cancer Res. Treat., Sep;105(1):87-94 (2007)
Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer.
J. Clin. Oncol., Jun;24(18):2793-9 (2006)
Residual tumor uptake of [99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival.
Cancer., Feb;103(4):680-8 (2005)
Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC).
Am. J. Clin. Oncol., Aug;27(4):407-10 (2004)
HER-2 testing in breast cancer using parallel tissue-based methods.
JAMA., Apr;291(16):1972-7 (2004)
Potential of chemotherapy-herb interactions in adult cancer patients.
Support Care Cancer., Jun;12(6):454-62 (2004)
Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy.
J. Nucl. Med., Nov;44(11):1806-14 (2003)
Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer.
J. Clin. Oncol., Apr;15(4):1395-400 (1997)
Effect of delay in radiation in the combined modality treatment of breast cancer.
Int. J. Radiat. Oncol. Biol. Phys., Apr;26(1):23-35 (1993)
Alternating weekly doxorubicin and 5-fluorouracil/leucovorin followed by weekly doxorubicin and daily cyclophosphamide in stage IV breast cancer. A Southwest Oncology Group study.
Cancer., Sep;68(5):934-9 (1991)
Cisplatin and novobiocin in the treatment of non-small cell lung cancer. A Southwest Oncology Group study.
Cancer., Jun;67(12):2969-73 (1991)
Bone marrow involvement in epithelial ovarian cancer by immunocytochemical assessment.
Gynecol. Oncol., Sep;38(3):442-5 (1990)
Combination chemotherapy and high-dose cyclophosphamide intensification for poor prognosis breast cancer. A Southwest Oncology Group Study.
Cancer., Dec;64(12):2409-15 (1989)